SCHEMBL922133

SCHEMBL922133

NC1=NN=C(N)C1=NNc1cccc2nsnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.47
KDM4E B2RXH2 8/20 0.47
HSD17B10 Q99714 5/20 0.47
HIF1A Q16665 1/20 0.47
MEN1 O00255 7/20 0.43
KMT2A Q03164 7/20 0.43
PKM P14618 1/20 0.43
ALDH1A1 P00352 9/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
RAB9A P51151 5/20 0.42
NPC1 O15118 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
HPGD P15428 6/20 0.40
HTT P42858 3/20 0.40
POLB P06746 2/20 0.40
NPSR1 Q6W5P4 2/20 0.39
PTK2B Q14289 1/20 0.39
TSHR P16473 2/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL922941 0.72 MEN1 (0.51) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL923905 0.70 PTPN11 (0.44) MAPTKDM4EHSD17B10MEN1KMT2A
SCHEMBL13866406 0.69 ALDH1A1 (0.53) MAPTKDM4EHSD17B10HIF1AMEN1
SCHEMBL924008 0.68 L3MBTL1 (0.38) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL396206 0.66 MAPT (1.00) MAPTKDM4EHSD17B10HIF1AMEN1
SCHEMBL22672943 0.66 KDM4E (0.49) MAPTKDM4EHSD17B10HIF1AMEN1
SCHEMBL923564 0.66 CYP3A4 (0.35) MAPTKDM4EPKMALDH1A1SMN1; SMN2
SCHEMBL12471994 0.65 MEN1 (0.49) MAPTKDM4EHSD17B10HIF1AMEN1
SCHEMBL12411184 0.65 ALDH1A1 (0.49) MAPTKDM4EHSD17B10HIF1AMEN1
SCHEMBL12403886 0.65 MAPT (0.49) MAPTKDM4EHSD17B10HIF1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US claimed
US-7105503-B2 Pyrazole compounds QLT INC. (CA) 2006-09-12 US claimed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US claimed
EP-1450791-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Kinetek Pharmaceuticals, Inc. (CA) 2004-09-01 EP claimed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 WO claimed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 US claimed
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 US disclosed
US-7105503-B2 Pyrazole compounds QLT INC. (CA) 2006-09-12 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 MAPT 4573/4885KDM4E 1193/4885HSD17B10 1881/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 MAPT 4573/4885KDM4E 1193/4885HSD17B10 1881/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC MAPT 4000/4885KDM4E 2760/4885HSD17B10 3914/4885
US-20030060453-A1 Pyrazole compounds CCNC, MKI67, CDC25C MAPT 4486/4885KDM4E 1067/4885HSD17B10 3118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.